Grifols Spon Adr Ea Repr 1 Ord Eur0.10 (GRFS) Stock
Global maker of plasma derived medicines and diagnostics. Here's the price, business snapshot, and what's worth knowing about Grifols Spon Adr Ea Repr 1 Ord Eur0.10 in May 2026.
Grifols, S.A. (GRFS) is a Barcelona‑based healthcare company best known for producing plasma‑derived medicines such as immunoglobulins, albumin and clotting factors. It operates a large plasma‑collection network and combines manufacturing with diagnostics and hospital products, giving diversified revenue streams across therapies and medical testing. Key drivers include demand for immune therapies, new product approvals, and the scale of its plasma supply; conversely, the business is capital‑intensive and exposed to regulatory scrutiny, pricing pressure and fluctuations in plasma availability. Grifols has a global footprint and a market capitalisation of about $8.16bn, which can mean exposure to currency and regional regulatory developments. This summary is for educational purposes only and not personal financial advice; investing carries risks and may not be suitable for everyone.
Stock Performance Snapshot
Financial Health
Grifols is performing well with strong revenue, cash flow, and profit margins.
Dividend
Grifols' dividend yield of 1.79% indicates a moderate return for investors seeking dividends. If you invested $1000 you would be paid $17.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring GRFS
The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Plasma as core
An extensive plasma‑collection network underpins sales of immunoglobulins and other therapies; supply and pricing can vary, which affects revenue.
Global footprint
Operations across Europe, the Americas and Asia offer market diversification but add currency and regulatory complexity for investors to monitor.
Balance‑sheet focus
Manufacturing and past acquisitions have resulted in notable indebtedness, so cash flow and debt metrics are closely watched by analysts.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
